glp for type 1 diabetes Ozempic and Other Off-Label Drugs Scripts for GLP-1, SGLT2 Drugs
Description
Stopping or interrupting GLP-1s for 6 months or more raised the risk for adverse cardiovascular events
GLP-1 receptor agonist as adjuvant therapy in Type 1 diabetes: No apparent benefit for Beta-Cell function or glycemia
Plaintiffs must serve expert reports on these issues by July 16, and defendants have until August 13, 2025
The pharmaceutical landscape has been transformed by Ozempic, which has led to a breakthrough in diabetes and weight management
These side effects are most frequent during the initial weeks and when increasing the dose but tend to improve over time
reviewed oncological FDG PET-CT scans of patients actively taking GLP-1 receptor agonists
